1. Home
  2. TWST vs PTGX Comparison

TWST vs PTGX Comparison

Compare TWST & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Twist Bioscience Corporation

TWST

Twist Bioscience Corporation

HOLD

Current Price

$163.58

Market Cap

9.2B

Sector

Health Care

ML Signal

HOLD

Logo Protagonist Therapeutics Inc.

PTGX

Protagonist Therapeutics Inc.

HOLD

Current Price

$143.70

Market Cap

9.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TWST
PTGX
Founded
2013
2006
Country
United States
United States
Employees
N/A
141
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.2B
9.3B
IPO Year
2018
2016

Fundamental Metrics

Financial Performance
Metric
TWST
PTGX
Price
$163.58
$143.70
Analyst Decision
Buy
Strong Buy
Analyst Count
8
13
Target Price
$46.88
$108.23
AVG Volume (30 Days)
1.6M
465.5K
Earning Date
05-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
63.89
N/A
EPS
N/A
2.35
Revenue
$376,572,000.00
N/A
Revenue This Year
$18.91
$874.25
Revenue Next Year
$15.07
N/A
P/E Ratio
N/A
$61.15
Revenue Growth
20.32
N/A
52 Week Low
$23.30
$61.95
52 Week High
$163.70
$160.81

Technical Indicators

Market Signals
Indicator
TWST
PTGX
Relative Strength Index (RSI) 70.79 45.56
Support Level $39.81 $141.95
Resistance Level N/A $160.81
Average True Range (ATR) 8.92 5.12
MACD 1.47 -0.99
Stochastic Oscillator 94.55 26.15

Price Performance

Historical Comparison
TWST
PTGX

About TWST Twist Bioscience Corporation

Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Share on Social Networks: